Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (NY:HLN)

9.670 -0.140 (-1.43%)
Streaming Delayed Price Updated: 1:57 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 Next >
Under the Radar: Hidden Value Across the Atlantic – 3 Stocks to Watch
 
Via Benzinga
Brightseed and Haleon Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation
From Brightseed
Via Business Wire
KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover
KKR is closing in on a $2.9B takeover of Karo Healthcare after outbidding rivals, reinforcing its aggressive push into European healthcare. 
Via Benzinga
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%. 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Top 2 Risk Off Stocks That May Implode In August
 
Via Benzinga
Current Analysis: Haleon
Haleon (HLN​​​​​​​) is one of the largest consumer health companies in the world. Over the past year, Haleon PLC share price rose 13.8% from $7.60 to $8.66 as of Tuesday’s market close. 
Via Talk Markets
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half. 
Via Benzinga
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion. 
Via Benzinga
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth. 
Via Benzinga
What's Going On With Kenvue Stock Monday?
Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. 
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Haleon Earnings Preview
 
Via Benzinga
Peering Into Haleon's Recent Short Interest
 
Via Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Elf Beauty appeared to rally along with KVUE on Monday. 
Via Investor's Business Daily
Topics Stocks
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
Via Benzinga
4 Reasons Pfizer Could Be a Value Play You Can't Miss
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71 
Via MarketBeat
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company. 
Via Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth... 
Via Benzinga
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon. 
Via Benzinga
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial... 
Via Benzinga
Robitussin Recall 2024: What to Know About the New Cough Syrup Recalls
A Robitussin recall is underway for two of the company's products after discovering microbial contamination of its cough syrups. 
Via InvestorPlace
Robitussin Recall: Here Are The Products Impacted And What You Need To Know
Haleon PLC (NYSE: HLN) announced a product recall of some of its Robitussin brand cough syrups. What Happened: A microbial contamination in Robitussin cough syrups could potentially cause... 
Via Benzinga
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.